MA48776A - Formes solides cristallines de sels de n-{4-[(6,7-diméthoxyquinolin-4-yl) oxy]phényl}-n'-(4-fluorphényl) cyclopropane-1,1-dicarboxamide, procédés de préparation et d'utilisation - Google Patents

Formes solides cristallines de sels de n-{4-[(6,7-diméthoxyquinolin-4-yl) oxy]phényl}-n'-(4-fluorphényl) cyclopropane-1,1-dicarboxamide, procédés de préparation et d'utilisation

Info

Publication number
MA48776A
MA48776A MA048776A MA48776A MA48776A MA 48776 A MA48776 A MA 48776A MA 048776 A MA048776 A MA 048776A MA 48776 A MA48776 A MA 48776A MA 48776 A MA48776 A MA 48776A
Authority
MA
Morocco
Prior art keywords
dimethoxyquinolin
fluorphenyl
dicarboxamide
cyclopropane
oxy
Prior art date
Application number
MA048776A
Other languages
English (en)
French (fr)
Inventor
Khalid Shah
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62683441&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA48776(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of MA48776A publication Critical patent/MA48776A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
MA048776A 2017-05-26 2018-05-26 Formes solides cristallines de sels de n-{4-[(6,7-diméthoxyquinolin-4-yl) oxy]phényl}-n'-(4-fluorphényl) cyclopropane-1,1-dicarboxamide, procédés de préparation et d'utilisation MA48776A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762511714P 2017-05-26 2017-05-26

Publications (1)

Publication Number Publication Date
MA48776A true MA48776A (fr) 2020-04-08

Family

ID=62683441

Family Applications (1)

Application Number Title Priority Date Filing Date
MA048776A MA48776A (fr) 2017-05-26 2018-05-26 Formes solides cristallines de sels de n-{4-[(6,7-diméthoxyquinolin-4-yl) oxy]phényl}-n'-(4-fluorphényl) cyclopropane-1,1-dicarboxamide, procédés de préparation et d'utilisation

Country Status (20)

Country Link
US (3) US11279675B2 (enExample)
EP (1) EP3630726B1 (enExample)
JP (3) JP7166292B2 (enExample)
KR (1) KR102611445B1 (enExample)
CN (1) CN110621662B (enExample)
AU (1) AU2018272088C1 (enExample)
CA (1) CA3060370A1 (enExample)
DK (1) DK3630726T3 (enExample)
EA (1) EA039654B1 (enExample)
ES (1) ES2909390T3 (enExample)
HU (1) HUE058196T2 (enExample)
IL (1) IL270780B2 (enExample)
MA (1) MA48776A (enExample)
MX (1) MX2019012505A (enExample)
PL (1) PL3630726T3 (enExample)
PT (1) PT3630726T (enExample)
SG (1) SG11201909161PA (enExample)
UA (1) UA127760C2 (enExample)
WO (1) WO2018218233A1 (enExample)
ZA (1) ZA201906127B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015218236B2 (en) * 2014-02-14 2019-06-13 Exelixis, Inc. Crystalline solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use
IL270780B2 (en) * 2017-05-26 2025-04-01 Exelixis Inc Crystalline solid forms of salts of N–{4–[(7,6–dimethoxyquinolin–4–yl)oxy]phenyl}–N'–(4–fluorophenyl)cyclopropane–1,1–dicarboxamide, processes for preparation and methods of use
GEAP202415420A (en) 2018-01-26 2024-12-25 Exelixis Inc Compounds for the treatment of kinase-dependent disorders
CN120305263A (zh) 2018-06-15 2025-07-15 汉达癌症医药责任有限公司 卡博替尼的盐类于制备治疗癌症的剂型的用途
EP4631505A3 (en) * 2018-12-13 2025-12-10 Exelixis, Inc. Crystalline forms and salt forms of a kinase inhibitor
SG11202111978VA (en) * 2019-06-03 2021-11-29 Exelixis Inc Crystalline salt forms of a kinase inhibitor
WO2023165948A1 (en) 2022-03-01 2023-09-07 Synthon B.V. Cabozantinib salt with l-(+)-tartaric acid and solid forms thereof
AU2024215796A1 (en) 2023-01-31 2025-05-15 Handa Oncology, Llc Improved cabozantinib compositions and methods of use
US11814356B1 (en) 2023-03-29 2023-11-14 Apotex Inc. Salt of cabozantinib

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2744997A1 (en) 2003-09-26 2005-04-07 Exelixis, Inc. C-met modulators and method of use
EA038195B1 (ru) 2009-01-16 2021-07-22 Экселиксис, Инк. Малатная соль n-(4-{[6,7-бис-(метилокси)хинолин-4-ил]окси}фенил)-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида и ее применение для лечения рака почек и печени
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
US20120070368A1 (en) 2010-04-16 2012-03-22 Exelixis, Inc. Methods of Using C-Met Modulators
WO2012009722A1 (en) 2010-07-16 2012-01-19 Exelixis, Inc. C-met modulator pharmaceutical compositions
CN103391773A (zh) 2010-09-27 2013-11-13 埃克塞里艾克西斯公司 用于治疗去势抵抗性前列腺癌和成骨性骨转移的met和vegf的双重抑制剂
DK2621481T4 (da) 2010-09-27 2023-01-09 Exelixis Inc Dobbelte inhibitorer af MET og VEGF til behandling af kastrationsresistent prostatacancer og osteoblastiske knoglemetastaser
TWI640509B (zh) 2011-02-10 2018-11-11 艾克塞里克斯公司 製造喹啉化合物之方法及包含該化合物之醫藥組合物
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
TWI610918B (zh) 2011-05-02 2018-01-11 艾克塞里克斯公司 治療癌症及骨癌疼痛之方法
GEP201606523B (en) 2011-09-22 2016-08-10 Exelixis Inc Method for treating osteoporosis
WO2013066296A1 (en) 2011-10-31 2013-05-10 Hewlett-Packard Development Company, L.P. Method of fabricating a color filter array using a multilevel structure
EP2776033A1 (en) 2011-11-08 2014-09-17 Exelixis, Inc. Dual inhibitor of met and vegf for treating cancer
EP2775921A1 (en) 2011-11-08 2014-09-17 Exelixis, Inc. Method of quantifying cancer treatment
CN104649969B (zh) 2013-11-22 2019-02-12 广东东阳光药业有限公司 一种替尼类药物的盐及其制备方法
AU2015218236B2 (en) * 2014-02-14 2019-06-13 Exelixis, Inc. Crystalline solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use
WO2015177758A1 (en) * 2014-05-23 2015-11-26 Mylan Laboratories Ltd Novel polymorphs of cabozantinib (s)-malate and cabozantinib free base
CN104961680B (zh) 2014-11-07 2017-09-12 苏州晶云药物科技有限公司 N‑(4‑{[6,7‑双(甲基氧基)喹啉‑4‑基]氧基}苯基)‑n’‑(4‑氟苯基)环丙烷‑1,1‑二甲酰胺的盐酸盐及其多晶型
CN104961681B (zh) 2014-11-13 2017-06-13 苏州晶云药物科技有限公司 卡博替尼的粘酸盐及其晶型
EP3274333B1 (en) * 2015-03-25 2019-04-24 Sandoz AG Cabozantinib salts and their use as anti-cancer agents
WO2016150966A1 (en) 2015-03-25 2016-09-29 Sandoz Ag Crystalline forms of cabozantinib phosphate and cabozantinib hydrochloride
US10980792B2 (en) * 2016-09-12 2021-04-20 Zhuhai Beihai Biotech Co., Ltd. Formulations of Cabozantinib
WO2018104954A1 (en) * 2016-12-07 2018-06-14 Msn Laboratories Private Limited, R&D Center Process for the preparation of n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide, (2s)-hydroxybutanedioate and its polymorphs thereof
IL270780B2 (en) * 2017-05-26 2025-04-01 Exelixis Inc Crystalline solid forms of salts of N–{4–[(7,6–dimethoxyquinolin–4–yl)oxy]phenyl}–N'–(4–fluorophenyl)cyclopropane–1,1–dicarboxamide, processes for preparation and methods of use

Also Published As

Publication number Publication date
KR20200010205A (ko) 2020-01-30
JP7166292B2 (ja) 2022-11-07
US20220162166A1 (en) 2022-05-26
CN110621662A (zh) 2019-12-27
CA3060370A1 (en) 2018-11-29
AU2018272088C1 (en) 2022-09-22
ZA201906127B (en) 2022-11-30
DK3630726T3 (da) 2022-03-07
EA039654B1 (ru) 2022-02-22
EP3630726A1 (en) 2020-04-08
US11279675B2 (en) 2022-03-22
EA201992803A1 (ru) 2020-04-16
JP2022145852A (ja) 2022-10-04
US11731941B2 (en) 2023-08-22
IL270780B1 (en) 2024-12-01
US20210261509A1 (en) 2021-08-26
JP2020521732A (ja) 2020-07-27
EP3630726B1 (en) 2021-12-22
IL270780B2 (en) 2025-04-01
WO2018218233A1 (en) 2018-11-29
UA127760C2 (uk) 2023-12-27
CN110621662B (zh) 2023-06-23
AU2018272088B2 (en) 2022-06-16
SG11201909161PA (en) 2019-10-30
AU2018272088A8 (en) 2019-10-24
IL270780A (en) 2020-01-30
NZ757564A (en) 2025-05-02
HUE058196T2 (hu) 2022-07-28
JP7437460B2 (ja) 2024-02-22
JP2024036690A (ja) 2024-03-15
JP7659097B2 (ja) 2025-04-08
ES2909390T3 (es) 2022-05-06
US20240010621A1 (en) 2024-01-11
MX2019012505A (es) 2019-12-19
PT3630726T (pt) 2022-03-02
PL3630726T3 (pl) 2022-05-09
AU2018272088A1 (en) 2019-10-17
US12227481B2 (en) 2025-02-18
KR102611445B1 (ko) 2023-12-06

Similar Documents

Publication Publication Date Title
IL270780A (en) Crystalline solid forms of salts of n-{4-[(6,7-dimethoxyquinolin-4-yl) oxy]phenyl}-n'-(4-fluorphenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
BR112016018450A2 (pt) formas sólidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida, processos de preparo e métodos de uso
MA52492A (fr) Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associés
MA50045A (fr) Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci
EP3271352A4 (en) PIPERAZINE CARBAMATES AND PROCESS FOR THE PREPARATION AND USE THEREOF
MA50041A (fr) Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci
MA54563A (fr) Agents de comblement tissulaire à base de soie-acide hyaluronique et leurs procédés de préparation et d'utilisation
EP3551612A4 (en) PROCESS FOR THE PREPARATION OF N- (4- (6,7-DIMETHOXYQUINOLIN-4-YLOXY) PHENYL) -N '- (4-FLUOROPHENYL) CYCLOPROPANE-1, 1-DICARBOXAMIDE, (2S) -HYDROXYBUTANYEDIOOR AND ITS POLYDROXYBUTANYMATE
EP3644999A4 (en) COMPOSITIONS AND METHOD OF USING 2- (4-CHLOROPHENYL) -N - ((2- (2,6-DIOXOPIPERIDINE-3-YL) -1-OXOISOINDOLINE-5-YL) METHYL) -2,2-DIFLUOACETAMIDE
EP3399981A4 (en) SOLID FORMS OF 2- (4-CHLOROPHENYL) -N - ((2-2,6-DIOXOPIPER-IDIN-3-YL) -1-OX-O-SO-ISOLIN-5-YL) METHYL) -2,2-DIFLUOROETAMIDE AND THEIR PHARMACEUTICAL COMPOSITIONS AND USES
IL282006A (en) Treating essential tremor using (r)-2-(4-isopropylphenyl)-n-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide
MA44672A (fr) Procédé de traitement du cancer à cellules rénales à l'aide de n-(4-(6,7-diméthoxyquinolin-4-yloxy) phényl)-n'-(4-fluorophény)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate
EP3455226A4 (en) SPIROCYCLIC COMPOUNDS AND METHOD FOR THE PRODUCTION AND USE THEREOF
EP3412671A4 (en) TLR7 AGONISTEMALEATE SALT, CRYSTALLINE FORMS C, D AND E THEREFOR, PROCESS FOR THE PREPARATION AND USE OF MALEATE SALT AND CRYSTALLINE FORMS
EP3849437A4 (en) BONE GRATER AND METHOD OF USE
EP3456722A4 (en) CRISABOROL CRYSTAL SHAPES IN FREE FORM AND PRODUCTION METHOD AND USE THEREOF
MA50201A (fr) Comprimés de défériprone à libération retardée et procédés d'utilisation correspondants
EP3853352A4 (en) FUNCTIONALIZED TRUCK PLATE, PROCESS FOR ITS MANUFACTURE AND ITS USE
EP3723899A4 (en) FILTER AIDS FOR TREATMENT OF OIL AND METHOD OF MANUFACTURING AND USING THEREOF
MA55532A (fr) Composés de neuréguline-4 et procédés d'utilisation
EP3664797A4 (en) NR4A1 LIGANDS, PHARMACEUTICAL COMPOSITIONS, AND RELATED METHODS OF USE
MA52587A (fr) Composés d'azabenzimidazole et produit pharmaceutique
EA201890896A1 (ru) Твердый препарат для перорального применения, содержащий аморфный солифенацин, и способ его получения
EP3404020A4 (en) PYRIDINOL DERIVATIVE OR PHARMACEUTICALLY SAFE SALT THEREOF AND PHARMACEUTICAL COMPOSITION THEREFORE AS AN ACTIVE SUBSTANCE
EP3736280A4 (en) SWEETENING COMPOSITION AND MANUFACTURING METHOD AND USE THEREOF